FDMT
4D Molecular Therapeutics Inc

1,241
Mkt Cap
$619.34M
Volume
862,359.00
52W High
$12.34
52W Low
$2.24
PE Ratio
-2.75
FDMT Fundamentals
Price
$10.95
Prev Close
$10.84
Open
$10.95
50D MA
$10.55
Beta
1.29
Avg. Volume
900,504.68
EPS (Annual)
-$2.98
P/B
1.37
Rev/Employee
$163.00
Loading...
Loading...
News
all
press releases
Redmile Group LLC Cuts Stake in 4D Molecular Therapeutics, Inc. $FDMT
Redmile Group LLC trimmed its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 88.8% during the 2nd quarter, according to the company in its most recent filing with the...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 5.3% - Here's Why
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 5.3% - Should You Sell...
MarketBeat·6d ago
News Placeholder
4D Molecular Therapeutics (NASDAQ:FDMT) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen cut shares of 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·10d ago
News Placeholder
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Decheng Capital LLC
Decheng Capital LLC lowered its holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 28.6% during the second quarter, according to its most recent disclosure with the Securities...
MarketBeat·12d ago
News Placeholder
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 7.4% - Here's What Happened
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 7.4% - Time to Sell...
MarketBeat·13d ago
News Placeholder
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are covering the firm, MarketBeat...
MarketBeat·23d ago
News Placeholder
Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the company's stock in a transaction on Monday, November 17th. The shares were sold at an...
MarketBeat·25d ago
News Placeholder
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2% - What's Next?
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 6.2% - Time to Buy...
MarketBeat·25d ago
News Placeholder
4DMT Appoints Kristian Humer As CFO
(RTTNews) - 4D Molecular Therapeutics, Inc. (FDMT), a biotechnology company, Monday announced that it has appointed Kristian Humer as its new chief financial officer...
Nasdaq News: Markets·29d ago
News Placeholder
4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded at Wall Street Zen
Wall Street Zen upgraded 4D Molecular Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·30d ago
<
1
2
...
>

Latest FDMT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.